Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Letairis Prior Auth | OpenPayer
    Ask Trek AI about this page
    RetiredVentura County Health Care PlanPolicy N/A

    Letairis (ambrisentan) Prior Authorization

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization for Letairis (ambrisentan) for pulmonary arterial hypertension, WHO Group I, under Ventura County Health Care Plan.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyLetairis (ambrisentan) Prior Authorization
    Policy CodePolicy N/A
    Change TypeArchivedno material changes
    Effective DateOct 20, 2014
    Last ReviewJan 22, 2019
    Next Review DateN/A
    Key ActionRequest prior authorization for Letairis when prescribed for pulmonary arterial hypertension, WHO Group I, to improve exercise ability and delay clinical worsening.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    WHO Group ISupported PAH group
    5 mg dailyRecommended starting dose
    10 mg dailyMaximum dose
    PregnancyContraindication
    Archived 01/22/19Policy disposition

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Authorization Criteria

    Authorization is supported when Letairis is prescribed for the covered indication and all of the following apply:

    Covered indication: The patient has pulmonary arterial hypertension (PAH), World Health Organization (WHO) Group I, and Letairis is being used to improve exercise ability and delay clinical worsening.

    Pregnancy is a contraindication to Letairis (ambrisentan) and should preclude coverage for use during pregnancy.

    Provider Actions

    Prior Authorization

    Request authorization for covered PAH use

    Request prior authorization for Letairis when it is prescribed for pulmonary arterial hypertension (PAH), World Health Organization (WHO) Group I, to improve exercise ability and delay clinical worsening.

    Denial Risk

    Unsupported indication may be denied

    Authorization is not supported when Letairis is requested for an indication other than pulmonary arterial hypertension (PAH) in WHO Group I.

    Denial Risk

    Contraindicated in pregnancy

    Do not use Letairis during pregnancy. Letairis is contraindicated in pregnancy.

    Background

    Letairis (ambrisentan) is an endothelin receptor antagonist selective for the endothelin type-A (ETA) receptor. By preventing the action of a potent paracrine peptide at the ETA receptor, it produces vasodilation. The policy identifies its use in WHO Group I pulmonary arterial hypertension to improve exercise ability and delay clinical worsening.

    Definitions

    PAH WHO Group I
    DefinitionPulmonary arterial hypertension classified as World Health Organization (WHO) Group I.
    Endothelin Type-A (ETA) Receptor
    DefinitionA receptor subtype targeted selectively by ambrisentan; blocking ETA-mediated effects contributes to vasodilation.

    Initial Therapy Criteria

    Initial Authorization

    Initial authorization is available when all of the following apply:

    Initial therapy: Letairis is being used for pulmonary arterial hypertension (PAH), World Health Organization (WHO) Group I, to improve exercise ability and delay clinical worsening.

    Quantity Limits

    Quantity Limit
    MedicationLetairis (ambrisentan)
    Maximum quantityUp to a maximum of 10 mg daily.
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyLetairis (ambrisentan) Prior Authorization
    Policy CodePolicy N/A
    Change TypeArchivedno material changes
    Effective DateOct 20, 2014
    Last ReviewJan 22, 2019
    Next Review DateN/A
    Key ActionRequest prior authorization for Letairis when prescribed for pulmonary arterial hypertension, WHO Group I, to improve exercise ability and delay clinical worsening.
    SourceLink
    On This Page
    Coverage CriteriaProvider ActionsBackgroundDefinitionsInitial Therapy CriteriaQuantity Limits